{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:47:54Z","timestamp":1782931674797,"version":"3.54.5"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.pcl.2021.07.011","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T21:26:51Z","timestamp":1635802011000},"page":"1171-1190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Precision Medicine in Pediatric Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Elizabeth A.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C.","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0889-8553(05)70064-9","article-title":"Inflammatory bowel disease in pediatric and adolescent patients","volume":"28","author":"Baldassano","year":"1999","journal-title":"Gastroenterol Clin North Am"},{"issue":"7","key":"10.1016\/j.pcl.2021.07.011_bib3","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ajg.2017.97","article-title":"Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases","volume":"112","author":"Benchimol","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2021.07.011_bib4","first-page":"S68","article-title":"The impact of inflammatory bowel disease in Canada 2018: IBD in seniors","volume":"2","author":"Nguyen","year":"2019","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cgh.2019.06.030","article-title":"Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review","volume":"18","author":"Kotze","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.pcl.2021.07.011_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s12889-019-6858-2","article-title":"A\u00a0four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia","volume":"19","author":"Mokhtar","year":"2019","journal-title":"BMC Public Health"},{"issue":"Suppl 2","key":"10.1016\/j.pcl.2021.07.011_bib7","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/ibd\/izz078","article-title":"Challenges in IBD research: precision medicine","volume":"25","author":"Denson","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.pcl.2021.07.011_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MPG.0000000000002556","article-title":"Anti-tumor necrosis factor-alpha exposure impacts vedolizumab mucosal healing rates in pediatric inflammatory bowel disease","volume":"70","author":"Jossen","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib14","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A\u00a0multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.pcl.2021.07.011_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/apt.14526","article-title":"Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation","volume":"47","author":"Gordon","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn's disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pcl.2021.07.011_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fped.2020.00400","article-title":"Cancer risk in pediatric-onset inflammatory bowel disease","volume":"8","author":"El-Matary","year":"2020","journal-title":"Front Pediatr"},{"issue":"7","key":"10.1016\/j.pcl.2021.07.011_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ncpgasthep0528","article-title":"Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis","volume":"3","author":"Sartor","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib19","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1053\/j.gastro.2020.12.034","article-title":"Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort","volume":"160","author":"Gettler","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.gastro.2019.11.006","article-title":"Prediction of inflammatory bowel disease: a step closer?","volume":"158","author":"Torres","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.pcl.2021.07.011_bib21","first-page":"1078","article-title":"Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the pediatric IBD porto group of ESPGHAN","volume":"11","author":"Birimberg-Schwartz","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/MPG.0b013e31805563f3","article-title":"Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America","volume":"44","author":"Bousvaros","year":"2007","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/00365521.2014.991752","article-title":"Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort","volume":"50","author":"Isene","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib25","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1136\/gutjnl-2017-314519","article-title":"Early intervention in Crohn's disease: towards disease modification trials","volume":"66","author":"Danese","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2020.07.065","article-title":"Predicting outcomes in pediatric Crohn's disease for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program","volume":"160","author":"Ricciuto","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(21)02421-5","article-title":"Su499 Long-term outcomes after primary ileocolic resection in pediatric crohn's disease in the biologic era: a single-center experience","volume":"160","author":"Spencer","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"10182","key":"10.1016\/j.pcl.2021.07.011_bib30","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(18)32592-3","article-title":"Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study","volume":"393","author":"Hyams","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pcl.2021.07.011_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cgh.2008.04.032","article-title":"Increased immune reactivity predicts aggressive complicating Crohn's disease in children","volume":"6","author":"Dubinsky","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.pcl.2021.07.011_bib32","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.3748\/wjg.v16.i21.2604","article-title":"Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease","volume":"16","author":"Dubinsky","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/00365521.2016.1259653","article-title":"Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy","volume":"52","author":"Olbj\u00f8rn","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"10080","key":"10.1016\/j.pcl.2021.07.011_bib34","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib35","first-page":"1335","article-title":"Serologic reactivity reflects clinical expression of ulcerative colitis in children","volume":"24","author":"Elizabeth","year":"2018","journal-title":"IBD"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.49.5.671","article-title":"High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis","volume":"49","author":"Fleshner","year":"2001","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ajg.2011.19","article-title":"The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis","volume":"106","author":"Adler","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"10014","key":"10.1016\/j.pcl.2021.07.011_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ng.3755","article-title":"Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease","volume":"49","author":"Lee","year":"2017","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1399-0039.2003.00129.x","article-title":"The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis","volume":"62","author":"Ahmad","year":"2003","journal-title":"Tissue Antigens"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib41","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1053\/gast.1997.v112.pm9178675","article-title":"Genetic markers may predict disease behavior in patients with ulcerative colitis","volume":"112","author":"Roussomoustakaki","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/apt.16136","article-title":"Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease","volume":"53","author":"Ungaro","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.pcl.2021.07.011_bib43","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.cgh.2018.09.008","article-title":"Association between plasma level of collagen type III alpha 1 chain and development of strictures in pediatric patients with Crohn\u2019s disease","volume":"17","author":"Ballengee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","article-title":"Development and validation of a test to monitor endoscopic activity in patients with Crohn's disease based on serum levels of proteins","volume":"158","author":"D'Haens","year":"2020","journal-title":"Gastroenterology"},{"issue":"Supplement_1","key":"10.1016\/j.pcl.2021.07.011_bib45","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1093\/ecco-jcc\/jjz203.431","article-title":"P302 Diagnostic accuracy of a serum-based biomarker panel for endoscopic activity in ulcerative colitis","volume":"14","author":"Holmer","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"issue":"10","key":"10.1016\/j.pcl.2021.07.011_bib46","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/ng.3936","article-title":"Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease","volume":"49","author":"Marigorta","year":"2017","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.pcl.2021.07.011_bib47","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gutjnl-2019-318343","article-title":"A\u00a0blood-based prognostic biomarker in IBD","volume":"68","author":"Biasci","year":"2019","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib48","doi-asserted-by":"crossref","first-page":"e026767","DOI":"10.1136\/bmjopen-2018-026767","article-title":"PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial","volume":"8","author":"Parkes","year":"2018","journal-title":"BMJ open"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib49","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2017.01.016","article-title":"Mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative Colitis from colon-only Crohn's disease in treatment-naive pediatric patients","volume":"152","author":"Rosen","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.pcl.2021.07.011_bib50","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1172\/JCI75436","article-title":"Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature","volume":"124","author":"Haberman","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.gastro.2016.10.012","article-title":"Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches","volume":"152","author":"Sartor","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.pcl.2021.07.011_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CEG.S186235","article-title":"Fecal microbiota profiles in treatment-na\u00efve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome","volume":"12","author":"Olbj\u00f8rn","year":"2019","journal-title":"Clin Exp Gastroenterol"},{"issue":"7687","key":"10.1016\/j.pcl.2021.07.011_bib54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature25172","article-title":"Precision editing of the gut microbiota ameliorates colitis","volume":"553","author":"Zhu","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib55","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/apt.13460","article-title":"A\u00a0validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables","volume":"43","author":"Siegel","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.pcl.2021.07.011_bib56","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.cgh.2020.02.010","article-title":"Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.15745","article-title":"Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment","volume":"52","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib59","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.pcl.2021.07.011_bib60","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib61","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib62","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of crohn's disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pcl.2021.07.011_bib63","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ibd\/izz251","article-title":"Mucosal eosinophilia is an independent predictor of vedolizumab efficacy in inflammatory bowel diseases","volume":"26","author":"Kim","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"461","key":"10.1016\/j.pcl.2021.07.011_bib64","doi-asserted-by":"crossref","first-page":"eaau4711","DOI":"10.1126\/scitranslmed.aau4711","article-title":"Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals","volume":"10","author":"Uzzan","year":"2018","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib65","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell host & microbe"},{"issue":"9940","key":"10.1016\/j.pcl.2021.07.011_bib66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: A Phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib68","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/ajg.2013.354","article-title":"EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging","volume":"108","author":"Faubion","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/ajg.2009.496","article-title":"Familial association of inflammatory bowel diseases with other autoimmune and related diseases","volume":"105","author":"Hemminki","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib70","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.pcl.2021.07.011_bib71","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Gasink C, Gao LL, et\u00a0al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367(16):1519-\u201328.","DOI":"10.1056\/NEJMoa1203572"},{"issue":"13","key":"10.1016\/j.pcl.2021.07.011_bib72","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Eng J Med"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.2010.46.4.1464839","article-title":"Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials","volume":"46","author":"Farhi","year":"2010","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.04.078","article-title":"Development and validation of a clinical decision support tool that incorporates pharmacokinetic data to predict endoscopic healing in patients treated with infliximab","volume":"19","author":"Vande Casteele","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.pcl.2021.07.011_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.02.010","article-title":"Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib77","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2468-1253(17)30252-2","article-title":"Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study","volume":"2","author":"Hyams","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.pcl.2021.07.011_bib78","doi-asserted-by":"crossref","first-page":"S072","DOI":"10.1093\/ecco-jcc\/jjy222.104","article-title":"DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease","volume":"13","author":"Verstockt","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.pcl.2021.07.011_bib79","author":"Administration UFaD"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib80","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib81","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib82","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.pcl.2021.07.011_bib83","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.2019.0709","article-title":"Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory Bowel disease","volume":"321","author":"Walker","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1\u221705 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib85","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2020.03.073","article-title":"Extended analysis identifies drug-specific association of 2 distinct HLA class ii haplotypes for development of immunogenicity to adalimumab and infliximab","volume":"159","author":"Powell Doherty","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.pcl.2021.07.011_bib86","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3093","article-title":"HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants","volume":"46","author":"Heap","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib87","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/apt.14483","article-title":"HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease","volume":"47","author":"Wilson","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.pcl.2021.07.011_bib88","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical Psoriasis Induced by Anti-TNF\u03b1 Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib89","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.pcl.2021.07.011_bib90","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pcl.2021.07.011_bib91","author":"Group"},{"issue":"8","key":"10.1016\/j.pcl.2021.07.011_bib92","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/ibd\/izy064","article-title":"What are the targets of inflammatory bowel disease management","volume":"24","author":"Lega","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.pcl.2021.07.011_bib93","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib94","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, or corticosteroid-free remission in patients with active luminal Crohn's disease","volume":"154","author":"D'Haens","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2019.05.029","article-title":"Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn's disease","volume":"18","author":"Dreesen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.pcl.2021.07.011_bib96","doi-asserted-by":"crossref","first-page":"S012","DOI":"10.1093\/ecco-jcc\/jjy222.017","article-title":"OP18 Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn\u2019s disease: the paediatric Crohn\u2019s disease adalimumab-level-based optimisation treatment (PAILOT) trial","volume":"13","author":"Assa","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib97","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A\u00a0test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.pcl.2021.07.011_bib98","first-page":"1079","article-title":"Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multicentre study","volume":"12","author":"Guidi","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.pcl.2021.07.011_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)30801-5","article-title":"240 real-world application of an adaptive dosing dashboard reveals accelerated induction dosing of infliximab is necessary in most IBD patients and improves therapuetic outcomes","volume":"158","author":"Dubinsky","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib100","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn's disease","volume":"109","author":"Xiong","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib101","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib102","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","article-title":"Development of infliximab target concentrations during induction in pediatric Crohn disease patients","volume":"69","author":"Clarkston","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.pcl.2021.07.011_bib103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-\u03b1 vs an immunomodulator in children with Crohn's disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pcl.2021.07.011_bib104","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: an open-label multicentre randomised controlled trial","author":"Jongsma","year":"2020","journal-title":"Gut"},{"issue":"10114","key":"10.1016\/j.pcl.2021.07.011_bib105","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.pcl.2021.07.011_bib106","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn's disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.pcl.2021.07.011_bib107","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib108","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2020","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.pcl.2021.07.011_bib109","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/gutjnl-2019-319451","article-title":"Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study","volume":"69","author":"Maaser","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.pcl.2021.07.011_bib110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2016.10.040","article-title":"Use of intestinal ultrasound to monitor Crohn's disease activity","volume":"15","author":"Kucharzik","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.pcl.2021.07.011_bib111","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.pcl.2021.07.011_bib112","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ordas","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.pcl.2021.07.011_bib113","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pcl.2021.07.011_bib114","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41395-018-0268-4","article-title":"Artificial intelligence-assisted gastroenterology- promises and pitfalls","volume":"114","author":"Ruffle","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.pcl.2021.07.011_bib115","doi-asserted-by":"crossref","first-page":"e00094","DOI":"10.14309\/ctg.0000000000000094","article-title":"Quality of life is associated with wearable-based physical activity in patients with inflammatory bowel disease: a prospective, observational study","volume":"10","author":"Wiestler","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"10.1016\/j.pcl.2021.07.011_bib116","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/apt.13641","article-title":"Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis","volume":"43","author":"Choung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib117","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.08.005","article-title":"Increased intestinal permeability is associated with later development of Crohn's disease","volume":"159","author":"Turpin","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pcl.2021.07.011_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(21)01929-6","article-title":"Sa473 risk profiling of unaffected members of families with a history of IBD using serology score, dysbiosis score, polygenic risk score, and fecal calprotectin","volume":"160","author":"Jacobs","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pcl.2021.07.011_bib119","doi-asserted-by":"crossref","first-page":"100884","DOI":"10.1016\/j.eclinm.2021.100884","article-title":"Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses","volume":"36","author":"Agrawal","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395521001309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395521001309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:24:47Z","timestamp":1758475487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395521001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0031395521001309"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2021.07.011","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Medicine in Pediatric Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2021.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}